Optune Lua received a CE Mark for treating metastatic NSCLC, used with immune checkpoint inhibitors or docetaxel after progression on a platinum-based regimen. The phase 3 LUNAR trial showed ...
The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...
Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division, offering ...
While USC’s offense adapts to a new quarterback calling plays this season, a transition in the defense’s huddle also might be completed by the Sept. 2 opener at Arkansas. Senior Oscar Lua started 11 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results